Takeda Commits US$100 Million To Regenerative Medicine Startup Ambys

Takeda has committed US$100 million to support the development of therapies for chronic liver diseases at Ambys.

AsianScientist (Aug. 23, 2018) – Ambys Medicines (Ambys), a California-based biotechnology company focused on the discovery and development of therapies for chronic liver disease, and Takeda Pharmaceutical Company Limited (Takeda) have announced that they have entered into a partnership to support the advancement of the Ambys platform and pipeline.

Takeda has committed US$100 million to the partnership, which includes participation in Ambys’ Series A financing. In return, Takeda receives an option to commercialization rights outside of the US for the first four products that reach an investigational new drug application created under the partnership.

“This partnership underscores the exciting potential we see to deliver on the promise of regenerative medicine for people with liver disease,” said Dr. Asit Parikh, head of the Gastroenterology Therapeutic Area unit at Takeda.

If Takeda elects to exercise an option for a product, Takeda will share in 50 percent of the development costs for any optioned program and will make development and regulatory milestone payments. Ambys retains full US rights.

“We are thrilled that Takeda has joined us at the outset to develop our vision to build a transformative approach to liver diseases. Ambys will undertake an intense and sustained effort to advance fundamental science and technology, while developing multiple programs aimed at diverse liver disease targets,” said Dr. Jeffrey Tong, CEO of Ambys.

“We are uniting a broad range of scientific innovators to help lead a new era of discovery and clinical translation for people with severe liver diseases, and we are delighted to join forces with Takeda in this important effort,” he added.


———

Source: Takeda; Photo: Shutterstock.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

Asian Scientist Magazine is an award-winning science and technology magazine that highlights R&D news stories from Asia to a global audience. The magazine is published by Singapore-headquartered Wildtype Media Group.

Related Stories from Asian Scientist